Markets, capital, and the discipline of patient investing.
RFC Capital Research publishes the independent analysis of Ruslan Averin — an investor focused on public markets, sovereign and corporate fixed income, cross-border real estate, and capital allocation across emerging and frontier markets.
No institutional mandate, no house view to defend — a working record of how one investor thinks about risk, value, and the markets most analysts avoid.
Citigroup Q3 2026 Preview: $2.65 EPS, a 13% RoTCE Run-Rate and the Banamex Clock
Citigroup Q3 2026 earnings preview: consensus EPS $2.65, revenue $23.7 billion, Fraser's 11% RoTCE target, Services growth, Banamex exit and the $30 billion buyback.
MarketsGameStop at $26.56: Half Portfolio, Half Retailer, One October Deadline
GameStop stock rose 48.6% in six weeks to $26.56. Record Q2 profit, a 9.8% eBay stake, $32 warrants expiring 30 October and a sum-of-parts check.
MarketsJ&J Q3 2026 Preview: A $1bn Charge, Talc Timetable and the DePuy Synthes Question
Johnson & Johnson Q3 2026 earnings preview: Firefly charge distorts EPS, Stelara erosion, $5.5 billion talc deal and the DePuy Synthes exit.
MarketsJPMorgan Q3 2026: Why the $105.5B NII Line Matters More Than the $5.93 EPS Bar
JPMorgan Q3 2026 earnings preview: consensus EPS $5.93, revenue $51.2B, NII guidance $105.5B, IB fees $3.0-3.1B and Dimon's economic read on 13 October.
MarketsOFZ Auctions Under Strain: Moscow Needs 2.45 Trillion Rubles in One Quarter
OFZ yields near 17%, a 7.345 trillion ruble deficit and failed auctions: how Russia funds its 2026 budget and who is actually buying the debt.
MarketsUnitedHealth Q3 2026 Preview: Why the Medical Care Ratio Outranks the $4.12 EPS Line
UnitedHealth Q3 2026 earnings preview: $4.12 EPS consensus, $111.3 billion revenue, 88.1% medical care ratio guidance and the 2027 Medicare Advantage question.
